34 results
8-K
EX-99.1
KROS
Keros Therapeutics Inc
12 Dec 22
Other Events
10:01am
of treatment in the completed Part 1. 58.1% (n=18/31) of these patients were classified as HTB. At baseline, transfusion-dependent patients exhibited biomarkers
8-K
EX-99.2
pw9efayfmgvqn2c
12 Dec 22
Other Events
10:01am
8-K
EX-99.1
4v4jelvydka5 m02
4 Aug 22
August 2022 Corporate Presentation
5:13pm
8-K
EX-99.2
v0cg 5sny9uu30k5owpg
10 Jun 22
Other Events
6:03am
8-K
EX-99.1
r0t0n 12z5ngo5cy0z
9 Mar 22
March 2022 Corporate Presentation
4:17pm
8-K
EX-99.2
1rhwq
13 Dec 21
Other Events
9:04am
8-K
EX-99.1
yo500s5 oh5b
4 Nov 21
November 2021 Corporate Presentation
9:24am
8-K
EX-99.3
eln777x3qrl7mlqm78
22 Jun 21
June 2021 Corporate Presentation
4:08pm
8-K
EX-99.1
fj2rz6hhugcpra fd
22 Jun 21
June 2021 Corporate Presentation
4:08pm